Erythromycin antagonizes the deceleration of gastric emptying by glucagon-like peptide 1 and unmasks its insulinotropic effect in healthy subjects

被引:102
作者
Meier, JJ
Kemmeries, G
Holst, JJ
Nauck, MA
机构
[1] Diabet Zentrum Bad Lauterberg, D-37431 Bad Lauterberg im Harz, Germany
[2] Ruhr Univ Bochum, Dept Med, D-4630 Bochum, Germany
[3] Univ Calif Los Angeles, Sch Med, Larry Hillblom Islet Res Ctr, Los Angeles, CA USA
[4] Univ Copenhagen, Panum Inst, Dept Med Physiol, DK-2200 Copenhagen, Denmark
关键词
D O I
10.2337/diabetes.54.7.2212
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Glucagon-like peptide 1 (GLP-1) has been proposed to act as an incretin hormone due to its ability to enhance glucose-stimulated insulin secretion. Because GLP-1 also decelerates gastric emptying, it physiologically reduces rather than augments postprandial insulin secretory responses. Therefore, we aimed to antagonize the deceleration of gastric emptying by GLP-1 to study its effects on insulin secretion after a meal. Nine healthy male volunteers (age 25 +/- 4 years, BMI 25.0 +/- 4.9 kg/m(2)) were studied with an infusion of GLP-1 (0.8 pmol (.) kg(-1) (.) min(-1) from -30 to 240 min) or placebo. On separate occasions, the prokinetic drugs metoclopramide (10 mg), domperidone (10 mg), cisapride (10 mg, all at -30 min per oral), or erythromycin (200 mg intravenously from -30 to -15 min) were administered in addition to GLP-1. A liquid test meal (50 g sucrose and 8% mixed amino acids in 400 ml) was administered at 0 min. Capillary and venous blood samples were drawn for the determination of glucose (glucose oxidase), insulin, C-peptide, GLP-1, glucagon, gastric inhibitory polypeptide (GIP), and pancreatic polypeptide (specific immunoassays). Gastric emptying was assessed by the phenol red dilution technique. Statistical analyses were performed using repeated-measures ANOVA and Duncan's post hoc test. GLP-1 significantly decelerated the velocity of gastric emptying (P < 0.001). This was completely counterbalanced by erythromycin, whereas the other prokinetic drugs used had no effect. Postprandial glucose concentrations were lowered by GLP-1 (P < 0.001 vs. placebo), but this effect was partially reversed by erythromycin (P < 0.05). Insulin secretory responses to the meal were lower during GLP-1 administration (P < 0.05 vs. placebo). However, when erythromycin was added to GLP-1, insulin concentrations were similar to those in placebo experiments. The suppression of meal-related increments in glucagon secretion by GLP-1 was reversed by erythromycin (P < 0.001). The time course of GIP secretion was delayed during GLP-1 administration (P < 0.05), but when erythromycin was added, the pattern was similar to placebo experiments. GLP-1 administration led to a reduction in pancreatic polypeptide plasma concentrations (P < 0.05). In contrast, pancreatic polypeptide levels were markedly increased by erythromycin (P < 0.001). Intravenous erythromycin counteracts the deceleration of gastric emptying caused by GLP-1, probably by interacting with the parasympathetic nervous system (pancreatic polypeptide responses). Despite augmented rises in insulin secretion, the glucose-lowering effect of GLP-1 is markedly reduced when the deceleration of gastric emptying is antagonized, illustrating the importance of this facet of the multiple antidiabetic actions of GLP-1.
引用
收藏
页码:2212 / 2218
页数:7
相关论文
共 45 条
[1]   GASTRIC INHIBITORY POLYPEPTIDE .1. AMINO ACID COMPOSITION AND TRYPTIC PEPTIDES [J].
BROWN, JC .
CANADIAN JOURNAL OF BIOCHEMISTRY, 1971, 49 (02) :255-&
[2]   GUT HORMONES AND DIABETES-MELLITUS [J].
CREUTZFELDT, W ;
NAUCK, M .
DIABETES-METABOLISM REVIEWS, 1992, 8 (02) :149-177
[3]   INCRETIN CONCEPT TODAY [J].
CREUTZFELDT, W .
DIABETOLOGIA, 1979, 16 (02) :75-85
[4]   Degradation of endogenous and exogenous gastric inhibitory polypeptide in healthy and in type 2 diabetic subjects as revealed using a new assay for the intact peptide [J].
Deacon, CF ;
Nauck, MA ;
Meier, J ;
Hücking, K ;
Holst, JJ .
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2000, 85 (10) :3575-3581
[5]   STIMULATION OF INSULIN-SECRETION BY GASTRIC INHIBITORY POLYPEPTIDE IN MAN [J].
DUPRE, J ;
ROSS, SA ;
WATSON, D ;
BROWN, JC .
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 1973, 37 (05) :826-828
[6]   Glucagon-like peptide 1 has a physiological role in the control of postprandial glucose in humans - Studies with the antagonist exendin 9-39 [J].
Edwards, CMB ;
Todd, JF ;
Mahmoudi, M ;
Wang, ZL ;
Wang, RM ;
Ghatei, MA ;
Bloom, SR .
DIABETES, 1999, 48 (01) :86-93
[7]   PLASMA INSULIN RESPONSE TO ORAL + INTRAVENOUS GLUCOSE ADMINISTRATION [J].
ELRICK, H ;
HLAD, CJ ;
ARAI, Y ;
STIMMLER, L .
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 1964, 24 (10) :1076-+
[8]   Receptor for motilin identified in the human gastrointestinal system [J].
Feighner, SD ;
Tan, CP ;
McKee, KK ;
Palyha, OC ;
Hreniuk, DL ;
Pong, SS ;
Austin, CP ;
Figueroa, D ;
MacNeil, D ;
Cascieri, MA ;
Nargund, R ;
Bakshi, R ;
Abramovitz, M ;
Stocco, R ;
Kargman, S ;
O'Neill, G ;
Van der Ploeg, LHT ;
Evans, J ;
Patchett, AA ;
Smith, RG ;
Howard, AD .
SCIENCE, 1999, 284 (5423) :2184-2188
[9]   Effect on glycemic control of exenatide (synthetic exendin-4) additive to existing metformin and/or sulfonylurea treatment in patients with type 2 diabetes [J].
Fineman, MS ;
Bicsak, TA ;
Shen, LZ ;
Taylor, K ;
Gaines, E ;
Varns, A ;
Kim, D ;
Baron, AD .
DIABETES CARE, 2003, 26 (08) :2370-2377
[10]   NEW CLINICAL METHOD FOR MEASURING RATE OF GASTRIC EMPTYING - DOUBLE SAMPLING TEST MEAL [J].
GEORGE, JD .
GUT, 1968, 9 (02) :237-&